{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:51:08Z","timestamp":1786542668234,"version":"build-2736575974"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"American Heart Association Scientific Development","award":["17SDG33400114"],"award-info":[{"award-number":["17SDG33400114"]}]}],"content-domain":{"domain":["jmmc-online.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular and Cellular Cardiology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.yjmcc.2019.08.011","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T23:08:44Z","timestamp":1567120124000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Death receptor 5 contributes to cardiomyocyte hypertrophy through epidermal growth factor receptor transactivation"],"prefix":"10.1016","volume":"136","author":[{"given":"Miles A.","family":"Tanner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby P.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel A.","family":"Grisanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yjmcc.2019.08.011_bb0005","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics-2017 update: a report from the American heart association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0010","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.111.224915","article-title":"Mechanisms of cell death in heart disease","volume":"32","author":"Konstantinidis","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0015","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1161\/01.RES.0000148632.35500.d9","article-title":"The mitochondrial death pathway and cardiac myocyte apoptosis","volume":"95","author":"Crow","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1023\/A:1011449708842","article-title":"Recent insights into the role of tumor necrosis factor in the failing heart","volume":"6","author":"Mann","year":"2001","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.yjmcc.2014.02.009","article-title":"beta-Adrenergic receptor-mediated transactivation of epidermal growth factor receptor decreases cardiomyocyte apopotsis through differential subcellular activation of ERK1\/2 and Akt","volume":"72","author":"Grisanti","year":"2014","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0030","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.277.5327.815","article-title":"An antagonist decoy receptor and a death domain-containing receptor for TRAIL","volume":"277","author":"Pan","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0035","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1369\/jhc.3A6112.2004","article-title":"Tissue distribution of the death ligand TRAIL and its receptors","volume":"52","author":"Spierings","year":"2004","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0040","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1044-579X(02)00131-1","article-title":"Cell surface death receptor signaling in normal and cancer cells","volume":"13","author":"Ozoren","year":"2003","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0045","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1177\/2047487317725017","article-title":"GDF-15 and TRAIL-R2 are powerful predictors of long-term mortality in patients with acute myocardial infarction","volume":"24","author":"Skau","year":"2017","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ejhf.980","article-title":"Circulating proteins as predictors of incident of heart failure in the elderly","volume":"20","author":"Stenemo","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0055","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1752854","article-title":"Roles and clinical applications of OPG and TRAIL as biomarkers in cardiovascular disease","volume":"2016","author":"Bernardi","year":"2016","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0060","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0065","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0378-4274(02)00422-8","article-title":"TRAIL-induced signalling and apoptosis","volume":"139","author":"MacFarlane","year":"2003","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0070","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/5517","article-title":"Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo","volume":"5","author":"Walczak","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0075","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.2009.25.1991","article-title":"Phase I dose-escalation study of recombinant human Apo2L\/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer","volume":"28","author":"Harbst","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0080","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.2009.25.4847","article-title":"Phase 1b study of dulanermin (recombinant human Apo2L\/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumad in patients with advanced non-squamous non-small-cell lung cancer","volume":"28","author":"Soria","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0085","doi-asserted-by":"crossref","first-page":"e702","DOI":"10.1038\/cddis.2013.214","article-title":"Resistance to TRAIL in non-transformed cells is sdue to multiple redundant pathways","volume":"4","author":"van Dijk","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0090","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.diff.2009.05.002","article-title":"Non-canonical role for the TRAIL receptor DR5\/FADD\/caspase pathway in the regulation of MyoD expression and skeletal myoblast differentiation","volume":"78","author":"Freer-Prokop","year":"2009","journal-title":"Differentiation"},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0095","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1074\/jbc.M115.713545","article-title":"The Deubiquitinase inhibitor PR-619 sensitizes normal human fibroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cell death","volume":"291","author":"Crowder","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0100","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","article-title":"Identification and characterization of a new member of the TNF family that induces apoptosis","volume":"3","author":"Wiley","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0105","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.7150\/thno.26619","article-title":"Pepducin-mediated cardioprotection via \u03b2-arrestin-biased \u03b22-adrenergic receptor-specific signaling","volume":"8","author":"Grisanti","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0110","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nchembio.1153","article-title":"Small-molecule activation of the TRAIL receptor DR5 in human cancer cells","volume":"9","author":"Wang","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0115","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/CIRCRESAHA.109.201418","article-title":"Loss of plakophilin-2 expression leads to decreased sodium current and slower conduction velocity in cultured cardiac myocytes","volume":"105","author":"Sato","year":"2009","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0120","doi-asserted-by":"crossref","first-page":"7460","DOI":"10.1128\/MCB.21.21.7460-7469.2001","article-title":"The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes","volume":"21","author":"Liang","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0125","doi-asserted-by":"crossref","first-page":"11257","DOI":"10.1073\/pnas.0401343101","article-title":"CCAAT displacement protein\/cut homolog recruits G9a histone lysine methyltransferase to repress transcription","volume":"101","author":"Nishio","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2174\/157489211796957757","article-title":"Regulating TRAIL receptor-induced cell death at the membrane: a deadly discussion","volume":"6","author":"Shirley","year":"2011","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0135","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ceb.2010.08.003","article-title":"Life and death in the thymus\u2014cell death signaling during T cell development","volume":"22","author":"Hernandez","year":"2010","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0140","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1440-1681.2007.04585.x","article-title":"Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure","volume":"34","author":"McMullen","year":"2007","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0145","first-page":"149","article-title":"Extracellular signal-regulated kinases 1\/2 as regulators of cardiac hypertrophy","volume":"6","author":"Mutlak","year":"2015","journal-title":"Front. Pharmaol."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0150","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.2147\/OTT.S73731","article-title":"Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line","volume":"8","author":"Yan","year":"2015","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0155","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1016\/j.ejca.2012.03.005","article-title":"TRAIL-activated EGFR by Cbl-b-regulated EGFR redistribution in lipid rafts atagonises TRAIL-induced apoptosis in gastric cancer cells","volume":"48","author":"Xu","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0160","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1158\/0008-5472.CAN-06-1224","article-title":"Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression","volume":"67","author":"Shrader","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0165","doi-asserted-by":"crossref","first-page":"10025","DOI":"10.1074\/jbc.M413673200","volume":"280","author":"Bremer","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0170","doi-asserted-by":"crossref","first-page":"86ra50","DOI":"10.1126\/scitranslmed.3001384","article-title":"Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation","volume":"3","author":"Dolloff","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/FJC.0000000000000462","article-title":"Cardiac GPCR-mediated EGFR transactivation: impact and therapeutic implications","volume":"70","author":"Grisanti","year":"2017","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0180","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/cas.12112","article-title":"Functional roles of tumor necrosis factor-related apoptosis-inducig ligand-DR5 interaction in B16F10 cells by activating the nuclear factor-kappaB pathway to induce metastatic potential","volume":"104","author":"Takahashi","year":"2013","journal-title":"Cancer Sci."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0185","first-page":"2770","article-title":"Molecular cloning and functional analysis of the mouse homologue of the KILLER\/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor","volume":"59","author":"Wu","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0190","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1536\/jhj.44.833","article-title":"Enhanced expression of the apoptosis inducing ligand TRAIL in mononuclear cells after myocardial infarction","volume":"44","author":"Nakajima","year":"2003","journal-title":"Jpn. Heart J."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0195","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2174\/157488709787047530","article-title":"TRAIL agonists on clinical trails for cancer therapy: the promises and the challenges","volume":"4","author":"Bellail","year":"2009","journal-title":"Rev. Recent Clin. Trials"},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0200","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pupt.2015.06.002","article-title":"Serum levels of tumor necrosis factor-related apoptosis-inducing ligand correlate with the severity of pulmonary hypertension","volume":"33","author":"Liu","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0205","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1165\/rcmb.2013-0490OC","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand regulates hallmark features of airways remodeling in allergic airways disease","volume":"51","author":"Collison","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0210","doi-asserted-by":"crossref","first-page":"16484","DOI":"10.1074\/jbc.M010384200","article-title":"MAPK\/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors","volume":"276","author":"Tran","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0215","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1080\/07357900500283036","article-title":"The activation of ERK1\/2 via a tyrosine kinase pathway attenuates trail-induced apoptosis in HeLa cells","volume":"23","author":"Lee","year":"2005","journal-title":"Cancer Investig."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0220","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.4161\/cc.8.8.8147","article-title":"How ERK1\/2 activation controls cell proliferation and cell death: is subcellular localization the answer?","volume":"8","author":"Mebratu","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0225","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1161\/01.RES.0000038488.38975.1A","article-title":"Involvement of extracellular signal-regulated kinases \u00bd in cardiac hypertrophy and cell death","volume":"91","author":"Bueno","year":"2002","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0230","doi-asserted-by":"crossref","first-page":"30245","DOI":"10.1074\/jbc.M102174200","article-title":"The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo","volume":"276","author":"Liang","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0235","doi-asserted-by":"crossref","first-page":"14471","DOI":"10.1073\/pnas.0602543103","article-title":"Gata4 is required for maintenance of postnatal cardiac function and the protection from pressure overload-induced heart failure","volume":"103","author":"Bisping","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0240","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/01.RES.0000215985.18538.c4","article-title":"Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy, compensation, and myocyte viability","volume":"98","author":"Oka","year":"2006","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0245","doi-asserted-by":"crossref","first-page":"12331","DOI":"10.1073\/pnas.1104499108","article-title":"Serine 105 phosphorylation of transcription factor GATA4 is necessary for stress-induced cardiac hypertrophy in vivo","volume":"108","author":"van Berlo","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0250","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/hh0202.104109","article-title":"Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor","volume":"90","author":"Thomas","year":"2002","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0255","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1161\/01.RES.82.12.1338","article-title":"Angiotensin II type 1 receptor-induced extracellular signal-regulated protein kiase activation is mediated by Ca2+\/calmodulin-dependent transactivation of epidermal growth factor receptor","volume":"82","author":"Murasawa","year":"1998","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0260","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1210\/me.2003-0309","article-title":"Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases","volume":"18","author":"Onan","year":"2004","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0265","doi-asserted-by":"crossref","first-page":"H316","DOI":"10.1152\/ajpheart.00635.2014","article-title":"Temporal and gefitinib-sensitive regulation of cardiac cytokine expression via chronic beta-adrenergic receptor stimulation","volume":"308","author":"Grisanti","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0270","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1172\/JCI31901","article-title":"Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confirs cardioprotection","volume":"117","author":"Noma","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0275","doi-asserted-by":"crossref","first-page":"34530","DOI":"10.1074\/jbc.M405703200","article-title":"Epidermal growth factor receptor transactivation mediates tumor necrosis factor-induced hepatocyte replication","volume":"279","author":"Argast","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0280","doi-asserted-by":"crossref","first-page":"G220","DOI":"10.1152\/ajpgi.00383.2010","article-title":"TNF transactivation of EGFR stimulates cytoprotective COX-2 expression in gastrointestinal epithelial cells","volume":"301","author":"Hobbs","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0285","doi-asserted-by":"crossref","first-page":"9268","DOI":"10.1074\/jbc.M110.179903","article-title":"The epidermal growth factor receptor mediates tumor necrosis facto-alpha-induced activation of the ERK\/GEF-H1\/RhoA pathway in tubular epitelium","volume":"286","author":"Kakiashvili","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0290","doi-asserted-by":"crossref","first-page":"11772","DOI":"10.1073\/pnas.0801463105","article-title":"Transactivation of EGF receptor and ErbB2 protects intestinal epithelial cells from TNF-induced apoptosis","volume":"105","author":"Yamaoka","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0295","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0300","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2174\/156800909789271495","article-title":"Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy","volume":"9","author":"van der Veeken","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0305","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3109\/07853890.2012.727019","article-title":"The role of osteoprotegrin in cardiovascular disease","volume":"45","author":"Montagnana","year":"2013","journal-title":"Ann. Med."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0310","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009012","article-title":"Osteoprotegerin and cardiovascular events in high-risk populations: meta-analysis of 19 prospective studies involving 27 450 participants","volume":"7","author":"Tschiderer","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183910","article-title":"Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: literature-based meda-analysis involving 26,442 participants","volume":"12","author":"Tschiderer","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0320","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ahj.2010.05.015","article-title":"Prognostic value of osteoprotegerin in chronic heart failure: the GISSI-HF trial","volume":"160","author":"Roysland","year":"2010","journal-title":"Am. Heart J."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0325","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10654-016-0172-4","article-title":"Plasma osteoprotegerin, its correlates, and risk of heart failure: a prospective cohort study","volume":"32","author":"di Giuseppe","year":"2017","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0330","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.jacc.2004.06.076","article-title":"Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction","volume":"44","author":"Ueland","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.yjmcc.2019.08.011_bb0335","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/cvr\/cvw025","article-title":"Cardiac hypertrophy is exacerbated in aged mice lacking the osteoprotegerin gene","volume":"110","author":"Hao","year":"2016","journal-title":"Cardiovasc. Res."}],"container-title":["Journal of Molecular and Cellular Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282819301725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282819301725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T18:14:47Z","timestamp":1571854487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022282819301725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":67,"alternative-id":["S0022282819301725"],"URL":"https:\/\/doi.org\/10.1016\/j.yjmcc.2019.08.011","relation":{},"ISSN":["0022-2828"],"issn-type":[{"value":"0022-2828","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Death receptor 5 contributes to cardiomyocyte hypertrophy through epidermal growth factor receptor transactivation","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular and Cellular Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yjmcc.2019.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}